Osteoarthritis: The Challenge of Establishing a Personalised Treatment - European Medical Journal

This site is intended for healthcare professionals

Continue

Osteoarthritis: The Challenge of Establishing a Personalised Treatment

Rheumatology
Download PDF

Summary of Presentations from the TRB Chemedica-Sponsored Satellite Symposium held at the Annual European Congress of Rheumatology – EULAR, Paris, France, on 11th June 2014

Chairpeople:
Johanne Martel-Pelletier , 1 Antonello Pietrangelo 2
Speakers:
Francis Berenbaum , 3 Jean-Pierre Pelletier , 4 Burkhard Leeb 5

1. Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Canada 
2. Unit of Internal Medicine and Metabolic Diseases, Centre for Hemochromatosis University Hospital, Modena, Italy 
3. University Pierre & Marie Curie, INSERM UMR-S938, AP-HP Saint-Antoine Hospital, Paris, France 
4. Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Canada
5. 2 nd Department of Medicine, Centre for Rheumatology, Lower Austria, State Hospital Stockerau, Karl Landsteiner Institute for Clinical Rheumatology, Stockerau, Austria

Acknowledgements:

Writing assistance provided by Dr Tom Priddle.

Citation:
EMJ Rheumatol. ;1[1]:33-39. DOI/10.33590/emjrheumatol/10312199. https://doi.org/10.33590/emjrheumatol/10312199.
Support:

The publication of this article was funded by TRB Chemedica International SA. The views and opinions expressed are those of the authors and not necessarily of TRB Chemedica International SA.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

The symposium, co-chaired by Prof Johanne Martel-Pelletier and Prof Antonello Pietrangelo, opened with a discussion of metabolic syndrome-associated osteoarthritis (OA) and a brief overview of treatment options by Prof Francis Berenbaum. Prof Jean-Pierre Pelletier then discussed the use of symptomatic slow-acting drugs for OA (SYSADOA) for knee OA within the context of the new European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) recommendations. Finally, Dr Burkhard Leeb concluded the session by discussing the indications, contraindications, and side-effect management of diacerein.

Please view the full content in the pdf above.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

We’ve noticed you’re accessing
from North/South America.